anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Liver ischemia-reperfusion injury (LIRI) is closely associated with immune infiltration, which commonly occurs after liver surgery, especially liver transplantation. Therefore, it is crucial to identify the genes responsible for LIRI and develop effective therapeutic strategies that target immune response. Methylation modifications in mRNA play various crucial roles in different diseases. This study aimed to identify potential methylation-related markers in patients with LIRI and evaluate the corresponding immune infiltration.
METHODS: Two Gene Expression Omnibus datasets containing human liver transplantation data (GSE12720 and GSE151648) were downloaded for integrated analysis. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were conducted to investigate the functional enrichment of differentially expressed genes (DEGs). Differentially expressed methylation-related genes (DEMRGs) were identified by overlapping DEG sets and 65 genes related to N6-methyladenosine (m6A), 7-methylguanine (m7G), 5-methylcytosine (m5C), and N1-methyladenosine (m1A). To evaluate the relationship between DEMRGs, a protein-protein interaction (PPI) network was utilized. The core DEMRGs were screened using three machine learning algorithms: least absolute shrinkage and selection operator, random forest, and support vector machine-recursive feature elimination. After verifying the diagnostic efficacy using the receiver operating characteristic curve, we validated the expression of the core DEMRGs in clinical samples and performed relative cell biology experiments. Additionally, the immune status of LIRI was comprehensively assessed using the single sample gene set enrichment analysis algorithm. The upstream microRNA and transcription factors of the core DEMRGs were also predicted.
RESULTS: In total, 2165 upregulated and 3191 downregulated DEGs were identified, mainly enriched in LIRI-related pathways. The intersection of DEGs and methylation-related genes yielded 28 DEMRGs, showing high interaction in the PPI network. Additionally, the core DEMRGs YTHDC1, METTL3, WTAP, and NUDT3 demonstrated satisfactory diagnostic efficacy and significant differential expression and corresponding function based on cell biology experiments. Furthermore, immune infiltration analyses indicated that several immune cells correlated with all core DEMRGs in the LIRI process to varying extents.
CONCLUSIONS: We identified core DEMRGs (YTHDC1, METTL3, WTAP, and NUDT3) associated with immune infiltration in LIRI through bioinformatics and validated them experimentally. This study may provide potential methylation-related gene targets for LIRI immunotherapy.
OBJECTIVES: I. Determine the maximum tolerated dose of B43-genistein immunoconjugate in patients with recurrent B-cell acute lymphoblastic leukemia or non-Hodgkin's lymphoma. II. Determine the systemic B43-genistein exposure levels in these patients. III. Determine the antileukemic activity of this regimen in these patients. IV. Monitor the development of human antimouse antibody in these patients on this regimen.

OUTLINE: This is a dose escalation study. Patients receive B43-genistein immunoconjugate IV over 1 hour on days 1-3, 8-10, and 15-17. Treatment continues every 3 weeks in the absence of unacceptable toxicity or until disease progression. Cohorts of 3-6 patients receive escalating doses of B43-genistein immunoconjugate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 6 months.

PROJECTED ACCRUAL: A minimum of 3-15 patients will be accrued for this study.
Hair lotion which restores the colour contains S to strengthen the scalp and aid the formation of the natural pigment. Typically the lotion contains : washed sublimed sulphur 1.00 g; glycerol/alcohol soln. 98.55 g; lead acetate 0.45 g; patent blue 4, a trace. The pH of the prod. is adjusted to ca. 6. The lotion is applied daily to the scalp and lightly massaged in.
Cohort 2 may be conducted at selected clinical sites where MS treatment-naïve patients who are entering a new treatment paradigm will be sought. At the clinical site, patients will be qualified, consented, and a small amount (up to 1mL) of blood will be collected. Between approximately 1 week and 6 months of treatment on the new drug, the participant will be sent another blood collection kit for microsample collection and a brief questionnaire at home. A final sample will be collected between 3 and 6 months after the start of treatment. Within 6 months of initiating treatment, the site will be asked to provide information regarding the health and treatment status of the participant.
FIELD: medicine. ^ SUBSTANCE: substance of the invention involves application of a delta-like ligand DLL4 antagonist in preparing a drug for prevention or reduction of blood vessel loss and/or promotion of productive angiogenesis in a patient suffering ischemic injury or circulatory collapse. As the DLL4 antagonist, it contains an antibody or an antibody fragment which specifically binds DLL4 and blocks its binding with a Notch receptor. Also, the invention involves application of the delta-like ligand (DLL4) antagonist for prevention or reduction of blood vessel loss and/or promotion of productive angiogenesis in the patient suffering ischemic injury or circulatory collapse. ^ EFFECT: advantage of the invention consists in preparation of the drug for treating vascular and ischemic eye diseases. ^ 14 cl, 8 ex, 10 dwg
Yoga poses will be performed after the eccentric exercise of the four muscles group (elbow flexors and extensors, knee extensors and flexors) for a total time duration of 20-30 minutes. To induce delayed onset muscle soreness the participants will be asked to breathe and hold each yoga pose for 6-8 breaths. The participants will perform 6 sets of 10 repetitions of one repetition maximum eccentric drills of the elbow and knee with 3 minutes rest period between each set.
The invention relates to a nasal drop or a nasal spray for treating tonsillitis. The nasal drop or the nasal spray can be prepared from the effective component of single Indian kalimeris herb and can be also prepared from the effective component of the Indian kalimeris herb and other components. The nasal drop or nasal spray has the better component characteristic that the effective component of the Indian kalimeris herb contained in every one milliliter of the nasal drop or the nasal spray is close to the effective component contained in every 1g of raw Indian kalimeris herb. The better application method of the nasal drop or the nasal spray is as follow: 10-30ml of nasal drop or nasal spray is slowly dropped or injected into the naris of a patient to flows through the nasal cavity and flows into the mouth to be split, wherein one milliliter of the nasal drop or the nasal spray contains 1g of effective component of the Indian kalimeris herb. The nasal drop or the nasal spray only needs to be used for one time. The nasal drop or the nasal spray has no side effect, cannot cause discomfort, is suitable for children and adults and achieves the goal of radically treating the tonsillitis without injecting or taking medicines or performing an operation. The nasal drop or the nasal spray belongs to the secret prescription of ancestraltraditional Chinese medicine, and proved by long-term folk medical practice, the nasal drop or the nasal spray has special effect on the tonsillitis and has the radical treatment rate of more than 95 percent.
### Studies with atorvastatin

Brain hemorrhage was seen in a female dog treated with atorvastatin calcium for 3 months at a dose equivalent to 120 mg atorvastatin/kg/day. Brain hemorrhage and optic nerve vacuolation were seen in another female dog that was sacrificed in moribund condition after 11 weeks of escalating doses of atorvastatin calcium equivalent to up to 280 mg atorvastatin/kg/day. The 120 mg/kg dose of atorvastatin resulted in a systemic exposure approximately 16 times the human plasma area-under-the-curve (AUC, 0–24 hours) based on the maximum human dose of 80 mg/day. A single tonic convulsion was seen in each of 2 male dogs (one treated with atorvastatin calcium at a dose equivalent to 10 mg atorvastatin/kg/day and one at a dose equivalent to 120 mg atorvastatin/kg/day) in a 2-year study. No CNS lesions have been observed in mice after chronic treatment for up to 2 years at doses of atorvastatin calcium equivalent to up to 400 mg atorvastatin/kg/day or in rats at doses equivalent to up to 100 mg atorvastatin/kg/day. These doses were 6 to 11 times (mouse) and 8 to 16 times (rat) the human AUC (0–24) based on the maximum recommended human dose of 80 mg atorvastatin/day.

CNS vascular lesions, characterized by perivascular hemorrhages, edema, and mononuclear cell infiltration of perivascular spaces, have been observed in dogs treated with other statins. A chemically similar drug in this class produced optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion at a dose that produced plasma drug levels about 30 times higher than the mean drug level in humans taking the highest recommended dose.
1,213,571. Cephalosporins. BRISTOLMYERS CO. 5 Jan., 1968 [5 Jan., 1967], No. 871/68. Heading C2A. The invention comprises an α-pyridylthioacetamido cephalosporanic acid derivative of formula wherein A is H, OH, C 2-8  alkanoyloxy, benzyloxy, a quaternary ammonium radical especially pyridinium, quinolinium, picolinium or lutidinium, or, when taken together with M is a monovalent C-O bond; and M is H, a pharmaceutically acceptable non-toxic cation, an anionic charge when A is a quaternery NH 4  radical or, when taken together with A, is a monovalent C-O bond; and Z is 2,- 3,- or 4- pyridyl. The compounds are prepared by (a) reacting a compound of formula: wherein A and M have the above meaning, with an α-haloacetyl halide of formula in which Hal is chloro, bromo or iodo, or its functional equivalent as an acylating agent, in the presence of a base, to produce an α- haloacetamido compound of formula wherein A and M are as defined above, and (b) reacting the thus-prepared α-haloacetamido compound in the presence of a base with a mercaptan of formula Z-SH wherein Z has the above meaning. Salts are formed with inorganic cations e.g. sodium and potassium, organic amine cations e.g. triethylamine, procaine and N-ethylpiperidine and with inorganic acids e.g. hydrochloric and organic acids e.g. acetic and ascorbic. Typical compounds are 7-[a-(4-pyridylthio)-acetamido]cephalosporanic acid and 3-methyl-7-[α-(4-pyridylthio) acetamido-]-3-cephem-4-carboxylic acid monophosphate. The 3- and 4-pyridyl compounds are more active against gram-negative bacteria than the 2-pyridyl compound. A pharmaceutical composition for parenteral or oral administration to man and animals comprises an α-pyridylthio acetamido cephalosporanic acid of Formula I and a carrier. The compositions may be used for treating mastitis in cattle. The compounds may be used as nutritional supplements in animal feeds.
The invention discloses a zwitterion functionalized biodegradable oral nano drug delivery system and application thereof. Hyperbranched polycarbonate is obtained by carrying out ring opening polymerization on acrylate cyclic carbonate and mercaptoethanol, and then the hyperbranched polycarbonate and thiolated zwitterion are subjected to Michael addition reaction to obtain the zwitterion hyperbranched polycarbonate. The zwitterionic material is coated with protein drugs by a self-assembly technology, and then is subjected to ultraviolet crosslinking, so that the zwitterionic material has the capability of resisting an acidic environment after being orally taken to the stomach. Meanwhile, the surface zwitterionic compound can realize a more ideal mucus penetration effect. The nano delivery system based on the zwitterionic compound is beneficial to the uptake of epithelial cells, and avoids the risks of bacterial infection and the like caused by intestinal leakage. The system overcomes the defects of easy inactivation, easy degradation and poor absorption existing in the oral delivery process of the protein drug, and improves the bioavailability of the protein drug.
Note: We will conduct Ex 3 with participants who display destructive behavior reinforced by access to tangible items so that we can vary reinforcement quality using the results of a paired-stimulus preference assessment. Based on the TWML, we hypothesize that a large drop in reinforcement quality at the start of FCT will increase the probability of an extinction burst. Preventing such drops will lessen the probability of an extinction burst. Therefore, we will program a large drop in the quality of reinforcement in our quality-drop condition and ensure that the quality of reinforcement remains equal to the quality of reinforcement in baseline in the quality-hold condition. In Experiment 3, we will equate reinforcement rate (i.e., independent, VI 1.5-s schedules) and magnitude (i.e., each reinforcer delivery will be 20 s) across baseline and both FCT conditions.
INTRODUCTION: Anaplastic meningiomas, categorized as WHO grade 3 tumors, are rare and highly aggressive, accounting for 1-2% of all meningioma cases. Despite aggressive treatment, including surgery and Radiation, they exhibit a high recurrence rate and poor survival outcomes. The aggressive histopathological features emphasize the urgent need for effective management strategies.
METHODS: A retrospective multi-institutional analysis was conducted on patients with recurrent anaplastic meningioma who underwent re-irradiation between 2017 and 2023. Clinical, dosimetric, and outcome data were collected and analyzed, focusing on local control, progression free survival and treatment-related adverse events.
RESULTS: Thirty-four cases were analyzed, with a median follow-up 11 months after re-irradiation. Progression-free survival at 12 months was 61.9%, with higher doses correlating with better outcomes. Concomitant Bevacizumab improves progression-free survival and reduces the risk of radiation necrosis. CDKN2A homozygote deletion correlated with a higher risk of local failure. Symptomatic radiation necrosis occurred in 20.5% of cases, but its incidence was lower with concomitant Bevacizumab treatment.
CONCLUSION: Re-irradiation presents a viable option for recurrent anaplastic meningioma despite the associated risk of radiation necrosis. Higher doses with concomitant Bevacizumab improve clinical outcomes and reduce toxicity. Individualized treatment approaches are necessary, emphasizing the importance of further research to refine management strategies for this challenging disease.
The present invention relates to an anti-bacterial, anti-viral, and anti-fungus composition, its preparation and use. The composition of the present invention mainly includes the following three ingredients in an adequate ratio: (A) a metal compound having catalytic function; (B) ionic compound, and (C) an additive. The anti-bacterial, anti-virus, and anti-fungus composition of the present invention is capable of destroying viruses as well as killing bacterial and fungi. Therefore, the composition can be formulated as an aerosol and a film for applying to protection devices such as respirators, masks, gloves, filters, condoms, etc. The present composition can also be used in household, vehicle, hospital, school, restaurant, hotel, internet coffee shop for applying to filter of air-conditioner, tap, stool, interior of elevator and its keyboard. Additionally, the present composition can be applied to human being such as applying to hand, foot, genital organs, oral cavity, and the like in a lower dose to attain the effect of destroying bacteria, viruses, and fungi.
Participants will be asked to use a web-based (eHealth) exercise intervention for 3 months. This eHealth exercise intervention includes over 90, 10-minute exercise videos with options for exercise type, time, and intensity, customized to the weight of the infant. Users can either select up to three 10-minute videos to create a 10 to 30-minute workout or choose a 'Ready Made' workout that is either 10, 20, or 30-minutes long.
We report a case of pathological complete response to neoadjuvant chemotherapy for abscess-forming rectal cancer. A woman in her 60s visited her primary care physician because she noticed an increase in the quantity of vaginal discharge. An irregular mass of goose-egg size found on the right vaginal wall was diagnosed as adenocarcinoma on biopsy, and she was referred to our hospital. After further examination, the mass was diagnosed as RbP, cT4b(vaginal), cN1a, cM0, cStage Ⅲc rectal cancer with abscess formation. After 6 courses of CAPOX as neoadjuvant chemotherapy, rectal resection(combined resection of the posterior vaginal wall) was performed. Pathological diagnosis showed no tumor cells and lymph node metastasis. Four courses of CAPOX were administered as postoperative adjuvant chemotherapy. The patient is still alive 4 years after surgery, without recurrence. When neoadjuvant chemotherapy is successful, radical resection is possible, even in cases with abscess formation, and long-term survival can be expected.
This invention refer to a new series of chelating agent that will also act as a blocide. The chemical structures of the above chelating agent are as in formula (I) or (II), wherein X is selected from the group of N, P, AS, Sb, Bi; R is alkyl, alkenyl, alkynyl, aryl etc as per described detail in patent draft. M is selected from the group of C, Si, Ge, Sn, Pb, Se, Te, Po, S. The above chemical structure as a chelating agent will have the chelation capability in comparation with sodium EDTA also have the biocidal effect by modifying microorganism cell wall membrane permeability. The synthesis of the above series of chemicals is consisting of two steps, i.e.: 1) the monalkylation of mineral acid orits oxide; 2) the synthesis of Tris compound from monoalkyl mineral acid or its oxide with VA series or its oxide. The application of above series of chemicals could be of many applications for chelation and antibacterial uses for industry, medical, food, etc.
<P>PROBLEM TO BE SOLVED: To obtain an ameliorant for sleep disturbance, which has excellent effect on symptoms such as sleep disorder or sleep induction disturbance, sleep regulation action (regulation of period of REM sleep and non-REM sleep and amelioration of arousal dysfunction) on promotion of natural sleep and security of deep sleep and no adverse effect.  <P>SOLUTION: The ameliorant for sleep disorder having action on sleep promotion/sleep regulation comprises an extract of a plant of the genus Lepidium of the family Cruciferas. Concretely, the plant of the genus Lepidium of the family Cruciferas is Lepidium meyenii Walp. The ameliorant for sleep disorder comprises an extract of Lepidium meyenii Walp as an active ingredient. The liquors or the food or beverage having action on sleep promotion/sleep regulation comprises any of the ameliorants for sleep disorder.  <P>COPYRIGHT: (C)2007,JPO&INPIT
CC-1 is administered as a 3-hour short-term intravenous infusion started at the MTD dose level identified in the dose escalation part of the study or based on the discretion of the sponsors delegate and DSMB recommendation supported by preliminary safety and efficacy data to constitute a modified MTD, e.g. to be one or more dose levels lower than the MTD determined. Patients can be treated simultaneously during the dose expansion phase. Patients must be hospitalized during step dosing, i.e. from day 1-4 (last dosing on day 3) of the first cycle. Thereafter inpatient treatment (overnight stay) depends on the discretion of the investigator, an outpatient treatment is preferred.
NEW MATERIAL:The thiol protease-inhibiting substance [molecular weight, 10,000(by SDS-polyacrylamide gel electrophoresis); appearance, white amorphous powder; stable at 4-10pH; thermal stability, stable at 60 deg.C for 1hr; inhibition spectrum, completely inhibits the activity of thiol protease such as ficin, papain, etc. and little inhibits the bromelain activity and the activity of serine protease such as trypsin, etc.]. USE:Remedy for inflammation, renal hypertension, muscular dystrophy, SLE, etc. in which thiol protease is participating. PREPARATION:Human tumor cells and normal human cells are homogenized in the presence of an aqueous solvent and extracted by maintaining at a proper temperature for a proper time, and the obtained extract or the culture liquid of the above cell is subjected to the concentration, dialysis, etc. The product is treated with a proper combination of an adsorbent, a polar organic solvent, salting-out, etc. to obtain the objective thiol protease-inhibiting substance.
The purpose of the present invention is to provide an anti-SIRPalpha antibody which can be used as a tumor agent, and an anti-tumor agent comprising the antibody as an active ingredient. An antibody of the invention specifically binds to human sirpa and blocks binding of human sirpa to CD47, the antibody comprising: (a) A light chain CDRL1 consisting of the amino acid sequence represented by SEQ ID NO. 1; (b) A light chain CDRL2 consisting of the amino acid sequence represented by SEQ ID NO. 2; (c) A light chain CDRL3 consisting of the amino acid sequence represented by SEQ ID NO. 3; (d) A heavy chain CDRH1 composed of the amino acid sequence represented by SEQ ID NO. 4; (e) A heavy chain CDRH2 consisting of the amino acid sequence represented by SEQ ID No. 5, and (f) a heavy chain CDRH3 consisting of the amino acid sequence represented by SEQ ID No. 6; and the heavy chain constant region is that of human IgG4, phenylalanine at position 234 is replaced with alanine, leucine at position 235 is replaced with alanine, and serine at position 228 is further replaced with proline according to the EU index of Kabat et al.
Women have a two-fold increased risk of developing Alzheimer's disease (AD) than men, yet the underlying mechanisms of this sex-specific vulnerability remain unknown. Here, we aimed at determining in the 5XFAD mouse model whether deficits in prefrontal-dependent cognitive functions, which are impacted in the preclinical stages of AD, appear earlier in females, and whether these cognitive deficits are associated with alterations in the activity of prefrontal parvalbumin (PV)-neurons that regulate prefrontal circuits activity. We observed that 3.5-month-old 5XFAD females, but not males, display impairments in spatial short-term recognition memory, a function that relies on the integrity of the prefrontal cortex. Hippocampal-dependent cognitive functions were intact in both sexes. We then observed that 5XFAD females have more prefrontal PV neurons expressing the marker of chronic activity FosB; this was inversely correlated with prefrontal-dependent cognitive performances. Our findings show for the first time sex-specific, early deregulation of prefrontal PV neurons activity, which is associated with early appearance of prefrontal-dependent cognitive functions in 5XFAD females providing a potential novel mechanism to the increased risk to AD in females.